Reported relationships
Latest disclosed role at each company.
| Company | Last reported as | Report date | Published |
|---|---|---|---|
| MYRIAD GENETICS INCMYGN · Entity 5953 | Chief People Officer | March 12, 2026 | March 16, 2026 |
Disclosed balances
About these balances
Latest available filing per company, not a reconstructed current portfolio. Matching sequences show the last reported balance with all source rows expandable; grouping alone does not establish account ownership. Do not add unresolved positions together. Filings may omit unchanged positions, and amendments may correct only part of an older disclosure. Jointly reported shares are not necessarily this owner's personal holdings.
MYRIAD GENETICS INC
Report date March 12, 2026 · Filed March 16, 2026
| Security / award | Ownership account | Disclosed shares / units | Disclosure context |
|---|---|---|---|
| Common StockSEC Table I · non-derivative | Direct | 267,801 |
Ending reported balance
After 2026-03-14 transaction · row 3
3 source rows · reconciled sequenceRow 1 · 2026-03-12 · Grant · Acquired 173,196 · Balance 282,484 F1: Consists of time-based restricted stock units granted pursuant to the Issuer's 2017 Employee, Director and Consultant Equity Incentive Plan. Each restricted stock unit represents a contingent right to receive one share of the Issuer's common stock and vests in three equal annual installments beginning on the first anniversary of the grant date. Row 2 · 2026-03-13 · Tax withholding · Disposed 8,899 · Balance 273,585 F2: Represents shares of Common Stock withheld by the Issuer to satisfy tax withholding obligations in connection with the vesting of restricted stock units previously granted to the Reporting Person. The number of shares withheld was determined based on the closing price of Issuer's Common Stock on March 13, 2026. Row 3 · 2026-03-14 · Tax withholding · Disposed 5,784 · Balance 267,801 F2: Represents shares of Common Stock withheld by the Issuer to satisfy tax withholding obligations in connection with the vesting of restricted stock units previously granted to the Reporting Person. The number of shares withheld was determined based on the closing price of Issuer's Common Stock on March 13, 2026. |
Filing footnotes · ownership attribution and instrument terms
F1: Consists of time-based restricted stock units granted pursuant to the Issuer's 2017 Employee, Director and Consultant Equity Incentive Plan. Each restricted stock unit represents a contingent right to receive one share of the Issuer's common stock and vests in three equal annual installments beginning on the first anniversary of the grant date.
F2: Represents shares of Common Stock withheld by the Issuer to satisfy tax withholding obligations in connection with the vesting of restricted stock units previously granted to the Reporting Person. The number of shares withheld was determined based on the closing price of Issuer's Common Stock on March 13, 2026.
Transaction history
JSON APIPurchases/sales include open-market and private transactions. Plan disclosure applies to the filing; individual rows may differ. “Not disclosed” is not “unplanned.”
The cutoff filters transaction history only. Company summaries and owner relationships show the latest available disclosures. Parser corrections can improve historical records.
| Transaction date | Company | Activity / security | Shares / units | Reported price | Reported value | Details |
|---|---|---|---|---|---|---|
| March 14, 2026 Filed Mar 16, 2026 21:06 UTC | MYRIAD GENETICS INC MYGN · Entity 5953 | Tax withholdingCommon Stock | 5,784 | $4.66 | $26,953.44 |
DisclosureSEC source: 0001472827-26-000004 · wk-form4_1773695166.xml · nonDerivative · entry 3 Solaiman Shereen · CIK 0001472827 · Chief People Officer 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 267,801 F2 · shares: Represents shares of Common Stock withheld by the Issuer to satisfy tax withholding obligations in connection with the vesting of restricted stock units previously granted to the Reporting Person. The number of shares withheld was determined based on the closing price of Issuer's Common Stock on March 13, 2026. Read SEC document |
| March 13, 2026 Filed Mar 16, 2026 21:06 UTC | MYRIAD GENETICS INC MYGN · Entity 5953 | Tax withholdingCommon Stock | 8,899 | $4.66 | $41,469.34 |
DisclosureSEC source: 0001472827-26-000004 · wk-form4_1773695166.xml · nonDerivative · entry 2 Solaiman Shereen · CIK 0001472827 · Chief People Officer 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 273,585 F2 · shares: Represents shares of Common Stock withheld by the Issuer to satisfy tax withholding obligations in connection with the vesting of restricted stock units previously granted to the Reporting Person. The number of shares withheld was determined based on the closing price of Issuer's Common Stock on March 13, 2026. Read SEC document |
| March 12, 2026 Filed Mar 16, 2026 21:06 UTC | MYRIAD GENETICS INC MYGN · Entity 5953 | GrantCommon Stock | 173,196 | $0.00 | $0.00 |
DisclosureSEC source: 0001472827-26-000004 · wk-form4_1773695166.xml · nonDerivative · entry 1 Solaiman Shereen · CIK 0001472827 · Chief People Officer 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 282,484 F1 · shares: Consists of time-based restricted stock units granted pursuant to the Issuer's 2017 Employee, Director and Consultant Equity Incentive Plan. Each restricted stock unit represents a contingent right to receive one share of the Issuer's common stock and vests in three equal annual installments beginning on the first anniversary of the grant date. Read SEC document |
| March 01, 2026 Filed Mar 2, 2026 21:18 UTC | MYRIAD GENETICS INC MYGN · Entity 5953 | Tax withholdingCommon Stock | 1,675 | $4.61 | $7,721.75 |
DisclosureSEC source: 0001472827-26-000002 · wk-form4_1772486306.xml · nonDerivative · entry 1 Solaiman Shereen · CIK 0001472827 · Chief People Officer 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 109,288 F1 · shares: Represents shares of Common Stock withheld by the Issuer to satisfy tax withholding obligations in connection with the vesting of restricted stock units previously granted to the Reporting Person. The number of shares withheld was determined based on the closing price of Issuer's Common Stock on February 27, 2026. Read SEC document |
| March 14, 2025 Filed Mar 17, 2025 20:20 UTC | MYRIAD GENETICS INC MYGN · Entity 5953 | Tax withholdingCommon Stock | 6,060 | $10.07 | $61,024.20 |
DisclosureSEC source: 0001628280-25-013152 · wk-form4_1742242812.xml · nonDerivative · entry 2 Solaiman Shereen · CIK 0001472827 · Chief People Officer 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 110,963 F2 · shares: Represents shares withheld by the Company to satisfy tax withholding obligations in connection with the vesting of restricted stock units granted to the reporting person. The number of shares of Myriad common stock withheld was determined based on the closing price of Myriad common stock on March 14, 2025. Read SEC document |
| March 13, 2025 Filed Mar 17, 2025 20:20 UTC | MYRIAD GENETICS INC MYGN · Entity 5953 | GrantCommon Stock | 63,145 | $0.00 | $0.00 |
DisclosureSEC source: 0001628280-25-013152 · wk-form4_1742242812.xml · nonDerivative · entry 1 Solaiman Shereen · CIK 0001472827 · Chief People Officer 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 117,023 F1 · shares: Consists of time-based restricted stock units granted pursuant to the Company's 2017 Employee, Director and Consultant Equity Incentive Plan. Each restricted stock unit represents a contingent right to receive one share of the Company's common stock and vests in three equal annual installments beginning on the first anniversary of the grant date. Read SEC document |
| March 01, 2025 Filed Mar 3, 2025 21:36 UTC | MYRIAD GENETICS INC MYGN · Entity 5953 | Tax withholdingCommon Stock | 1,912 | $10.73 | $20,515.76 |
DisclosureSEC source: 0001472827-25-000002 · wk-form4_1741037773.xml · nonDerivative · entry 1 Solaiman Shereen · CIK 0001472827 · Chief People Officer 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 53,878 F1 · shares: Represents shares withheld by the Company to satisfy tax withholding obligations in connection with the vesting of restricted stock units granted to the reporting person. The number of shares of Myriad common stock withheld was determined based on the closing price of Myriad common stock on February 28, 2025. Read SEC document |
| March 14, 2024 Filed Mar 18, 2024 20:45 UTC | MYRIAD GENETICS INC MYGN · Entity 5953 | GrantCommon Stock | 41,042 | $0.00 | $0.00 |
DisclosureSEC source: 0001628280-24-011683 · wk-form4_1710794727.xml · nonDerivative · entry 1 Solaiman Shereen · CIK 0001472827 · Chief People Officer 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 55,790 F1 · kind: Consists of time-based restricted stock units granted pursuant to the Company's 2017 Employee, Director and Consultant Equity Incentive Plan. Each restricted stock unit represents a contingent right to receive one share of the Company's common stock and vests in three equal annual installments beginning on the first anniversary of the grant date. Read SEC document |
| March 01, 2024 Filed Mar 4, 2024 21:18 UTC | MYRIAD GENETICS INC MYGN · Entity 5953 | Tax withholdingCommon Stock | 1,108 | $22.18 | $24,575.44 |
DisclosureSEC source: 0001472827-24-000002 · wk-form4_1709586801.xml · nonDerivative · entry 1 Solaiman Shereen · CIK 0001472827 · Chief People Officer 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 14,748 F1 · kind: Represents shares withheld by the Company to satisfy tax withholding obligations in connection with the vesting of restricted stock units granted to the reporting person. The number of shares of Myriad common stock withheld was determined based on the closing price of Myriad common stock on March 1, 2024. Read SEC document |
| March 01, 2023 Filed Mar 2, 2023 21:13 UTC | MYRIAD GENETICS INC MYGN · Entity 5953 | GrantCommon Stock | 15,856 | $0.00 | $0.00 |
DisclosureSEC source: 0001472827-23-000006 · wf-form4_167779157228780.xml · nonDerivative · entry 1 Solaiman Shereen · CIK 0001472827 · Chief People Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 15,856 F1 · kind: Consists of time-based restricted stock units granted pursuant to the Company's 2017 Employee, Director and Consultant Equity Incentive Plan. Each restricted stock unit represents a contingent right to receive one share of the Company's common stock and vests in four equal annual installments beginning on the first anniversary of the grant date. Read SEC document |
Value uses the disclosed total when available, otherwise shares × reported transaction price. It is not an estimate of exercise cash cost or investment performance.